Increasing Immuno-Oncology Therapeutic Options for the Treatment of Advanced Non-Small Cell Lung Carcinoma: New and Emerging Agents
David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
This enduring activity will cover immuno-oncology therapeutic options for the treatment of advanced non-small cell lung carcinoma.
This activity is designed to meet the educational needs of medical/academic oncologists, community oncologists, advanced practitioners in oncology (NP/PA/PharmD), and nurses involved in the management of patients with advanced non-small cell lung carcinoma (NSCLC).
After completing the CME activity, learners should be better able to:
- Describe the mechanism of action of immune checkpoint inhibitors and their impact on tumor evasion and immune surveillance
- Examine clinical trial data supporting the use of immune checkpoint inhibitors in the treatment of NSCLC, and compare the efficacy and safety of these agents
- Explain the utility of biomarkers in predicting responsiveness to cancer immunotherapies and the selection of therapy for patients with NSCLC
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the management of patients with advanced NSCLC. Credits: 1.0 ANCC Contact Hour(s).
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Ettinger is a consultant for AstraZeneca, BeyondSpring Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co., Genentech, and Guardant Health, Inc.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online evaluation.
Participants will receive their certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at https://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: August 20, 2019
EXPIRATION DATE: August 20, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.